 "Johnson & Johnson delays vaccine rollout in Europe amid blood clot probe")
Johnson & Johnson says it is delaying the rollout of its coronavirus vaccine in Europe amid a US probe into rare blood clots.
The company announced the decision Tuesday after regulators in the United States said they were recommending a pause in administration of the single-dose shot to investigate reports of potentially dangerous blood clots.
We have been reviewing these cases with European health authorities, the company said. We have made the decision to proactively delay the rollout of our vaccine in Europe.
Hundreds of thousands of doses of the vaccine were due to be shipped to Europe in the coming weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app